Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
- 413 Downloads
Sarcomatoid renal cell cancer is associated with a very poor prognosis, characterized by rapid progression of advanced disease. We previously reported the outcome of 18 patients with advanced sarcomatoid renal cell cancer treated with a regimen consisting of doxorubicin, 50 mg/m2 and gemcitabine, 1,500–2,000 mg/m2, administered every two weeks with growth factor support (A/G). Among the 18 patients, there were two complete and 5 partial responses and two patients with stable disease of more than 6 months of duration. We now report long-term survival of 4 patients with stage IV sarcomatoid renal cell carcinoma treated with this regimen at the 1,500 mg/m2 dose of gemcitabine, and achieving complete response (2 patients), or rendered complete responders following surgery after maximum response (2 patients). The two complete responders are alive, disease free at 6+ and 8+ years after starting A/G, and the 2 patients rendered CR by surgery survived 3½ and 6 years, respectively. Both died of progressive disease, one with clear cell recurrence, one with sarcomatoid recurrence. In summary, this regimen is associated with a high response rate, overall improvement in progression free survival and occasional meaningful long-term survival in a disease expected to be fatal within one year.
KeywordsSarcomatoid renal cell cancer Survival Chemotherapy
Dr. Preston Steen for his excellent care in collaboration of patient 4 and Dr. Peter Wiernik for his review of this manuscript were acknowledged. This work was supported in part by Renal Cancer Research Fund, Cancer Research Foundation.
- 14.Haas N, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wildiing G, Dutcher JP : ECOG 8802: a phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features. Proc GU ASCO. 2009.Google Scholar
- 18.Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629–36.PubMedCrossRefGoogle Scholar
- 25.Tamboli P, Prieto VG, Bekele BN, et al. The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol. 2003;22:408a. (abst 1641).Google Scholar
- 27.Michaelson M, Schwarzberg A, Ryan D, McDermott D, Shapiro G, Tye L, Chen I, Selaru P, Wang E, Zhu A. a phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Proc GU ASCO 2008. Abst 362. 2008.Google Scholar
- 28.Michaelson D, McDermott DF, Atkins MB, Cho DC, Olivier KM, Schwarzberg AB, Choueiri TK: phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor risk metastatic renal cell carcinoma. Proc GU ASCO 2010. Abst 340. 2010.Google Scholar